Axinn, Veltrop & Harkrider LLP’s Post

We’re headed to California! Javara Co-founder and Chief Legal Officer Linda McCarty, JD has been invited to speak at the McDermott Will & Emery Pharma and Medtech Services Investment Summit THIS Thursday, May 2th in San Francisco. “Clinical Trial Site Management Organizations” is a session you won’t want to miss. More details below! #javara #javaralive #clinicalresearch #clinicaltrials #PharmaInvest2024 #conferences

I hope this will be recorded. Sigh. Bummed to be a little too far away. But, if you're in the Boston area, go see Jeny Maier talk about the M&A landscape for Pharma and Biotech industries. Important learnings to be gained here, for sure. #digitalhealth #lifesciences cc: Phase2

On November 16, Principal Pauline Kennedy will participate in the eighth Global Antitrust Economics Conference, sponsored by Concurrences and New York University. Serving on the panel “Antitrust in Life Sciences,” Dr. Kennedy and her co-panelists will discuss different aspects of antitrust and competition within the life sciences and health industries, including mergers and litigation. Learn more and register for this event: https://ow.ly/i8Mb50PUP8e #beyondexpertsbetterexperience #antitrust #lifesciences

"In the life sciences, M&A is a sign of health. If we see a slowdown in M&A, we see a slowdown in bringing new drugs to patients." During a recent webinar with PULSE (Partnership for the US Life Science Ecosystem), our executive director John Stanford discussed the vital role of mergers and acquisitions in the life sciences. Watch the webinar here: https://lnkd.in/gXEbGQX6

More than a year after the launch of Chapter 18C of the Listing Rules, Tencent-backed AI drug researcher QuantumPharm has finally debuted on the HKEX as the first IPO via the new regulations.    QuantumPharm debuted on the HKEX on 13 June, raising HKD989 million (USD127 million) from the issue of 187 million shares at HKD5.28 apiece.    Sidley Austin LLP acted as QuantumPharm’s Hong Kong and US counsel, and wrote the prospectus. In addition, Fangda Partners and Maples Group advised QuantumPharm. Herbert Smith Freehills and JunHe LLP advised the sole sponsor CITIC Securities and overall co-ordinators.    Meng Ding, one of the IPO lead partners at Sidley Austin, said “The Chapter 18C specialist technologies [regulation] covers five broad industries and 20 acceptable sectors … Each category of technologies is also deeply rooted in hard-to-understand sciences, which the general investing public is not familiar with and not used to encountering.”    📢 Join our membership: https://lnkd.in/gi5sZaTn    #lawdotasia #cblj #iblj #ablj #china #hongkong #hkex #ipo #capitalmarkets #inhousecounsel #business #legalprofession #lawfirms #lawyers #legal #law

Successful life sciences deal-making requires the ability to navigate the here and now while also trying to see around corners and predict the future. For those at BIO, join me tomorrow (June 5) for a deep dive into the current choppy waters of deal-making in the current markets, where I have the privilege of talking with Barbara Kosacz, Joseph Baroldi and Stacy Feld to share their insights and perspectives from decades of collective experience across various sectors of the life sciences and biotech industry, including roles as C-suite executives, investors, legal counsel, and board members in a range of life sciences companies and investment funds. https://lnkd.in/gz_ZKaBX

Hey, we know him! Watch the latest #NYSEFloorTalk to hear Cooley LLP partner Divakar Gupta's insight for companies contemplating going public + what he expects for the 2024 biotech IPO market. Be sure to tune in to our next installment of #CooleyMarketTalks, which will cover market activity across the life sciences and healthcare sectors + considerations for these companies preparing to go public. Register for the virtual event here: https://lnkd.in/esviNis8 #capitalmarkets #lifesciences #healthcare #biotech #NYSE #IPO

McDermott Will & Emery’s inaugural Pharma and MedTech Services Investment Summit brings together C-suite executives, private equity professionals, investment bankers, and other industry leaders for a deep dive into the investment opportunities and emerging trends shaping pharma and device services. BGL’s Head of Healthcare & Life Sciences John Riddle is a featured panelist for a session entitled, “Clinical Trial Site Management Organizations,” on Thursday, May 2nd from 2 -2:40 p.m. PT. BGL’s Diagnostics, Research Tools & Medical Devices investment banking team has decades of experience advising companies across the diagnostics and device landscape. With this in-depth knowledge and background, we have provided capital formation, technology strategy, and medical device M&A strategy for a wide range of diagnostics, research tools, and device companies. To learn more about our experience and capabilities in the Pharma and MedTech Services sectors, including our most recent transactions, visit: https://lnkd.in/g3fVKzYp #Investmentbanking #MergersAndAcquisitions #Healthcare #MedicalDevice #Pharma

Start the new year with fresh and relevant topics in an Athena Alliance peer group. It's a great way to meet other members and invest your time. I host the Sales & Marketing peer group, and we have a hot list of topics for Q1 and a deep well of cohosts. Join us on January 5th @ 9am PST! #executiveleadership #exeuctiveinsights #athenaalliance #salesandmarketing #CMO #salesexecutives

How can pharma companies regain shareholders' trust? Embracing the recent upswing in M&A is one way to do it, but only if it's done the right way, according to industry watchers like PwC's Greg Rotz and Allen & Overy's Nicole Daley. Read more at PharmaVoice.